Svelte Medical Systems
Svelte Medical Systems is a privately held medical device company founded in 2007 that designs and develops highly deliverable balloon expandable stents for interventional cardiology. It serves hospitals and physicians and has financed development through over $128 million in private capital across multiple funding rounds.
- Company typePrivate
- Founded2007
- HeadquartersNew Providence, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Svelte Medical Systems does
Svelte Medical Systems Inc is a privately held medical device company incorporated in Delaware in 2007 and headquartered in New Providence, New Jersey. The company is focused on the design and development of highly deliverable balloon expandable stents used in interventional cardiology. Its core technology centers on low-profile stent delivery systems intended to improve deliverability and reduce procedural complexity compared to conventional stent platforms. Leadership is anchored by Chairman and CTO Robert Fischell, a known medical device inventor, alongside President and CEO Jack Darby and a functional team covering R&D, quality assurance, operations, and sales and marketing.
The company has financed its development through multiple rounds of private capital raising, accumulating roughly $128 million across more than a decade from investors including CNF Investments, New Science Ventures, Savitr Capital, Apjohn Ventures, Norwich Ventures, and West Health Investment Fund. The largest rounds were a $44.4 million Series 4 in February 2016 and a $22 million round in October 2018, with a $5.4 million filing recorded in May 2021. The capital intensity and milestone-driven cadence of fundraising are consistent with a clinical-stage medical device company advancing through regulatory pathways rather than a scaled commercial enterprise.
The company employs between 11 and 50 staff and maintains a European Business Director, suggesting a cross-Atlantic commercial intent likely tied to CE Mark clearance. Publicly disclosed revenue, pricing, customer relationships, and product launch details are absent from available sources, and the company website currently displays a default nginx page, limiting visibility into current commercial status.
Svelte Medical Systems firmographics
Firmographics- Name
- Svelte Medical Systems
- Legal name
- Svelte Medical Systems Inc
- Website
- https://sveltemedical.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Svelte Medical Systems is a privately held medical device company founded in 2007 that designs and develops highly deliverable balloon expandable stents for interventional cardiology. It serves hospitals and physicians and has financed development through over $128 million in private capital across multiple funding rounds.
- Ownership category
- akta.pro rank
Svelte Medical Systems industry classification
Industry- Product category
- Interventional Cardiology Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)
- akta.pro secondary industry
- Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)
Keywords
Where Svelte Medical Systems is headquartered
LocationHeadquarters
- HQ city
- New Providence
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Svelte Medical Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
Svelte Medical Systems product offering
Product offeringCore offering
Svelte Medical Systems designs and develops highly deliverable balloon-expandable stents for use in interventional cardiology procedures. The company focuses on stent and delivery system engineering intended to enable treatment of complex coronary lesions. Its offerings target hospitals and cardiology practices performing percutaneous coronary intervention.
Differentiator
Problem solved
Functional benefit
Products and services
- Balloon-Expandable Coronary Stent System A highly deliverable balloon-expandable stent and delivery system designed for use by interventional cardiologists performing percutaneous coronary intervention in patients with coronary artery disease.
Companies that use Svelte Medical Systems
Customer profileIdeal customer profiles1 record
Svelte Medical Systems technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Svelte Medical Systems partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
Svelte Medical Systems competitors and assessment
Company assessmentBroad incumbents
- Abbott Vascular: Abbott's vascular division markets the Xience family of drug-eluting stents, the global volume leader in coronary stents. It competes head-on with Svelte's target category and sets the benchmark Svelte must differentiate against on deliverability.
- Medtronic: Medtronic sells the Resolute Onyx and Endeavor drug-eluting stent platforms and is one of the two largest coronary stent franchises globally. Comparable as the dominant incumbent Svelte must displace or partner with in cath labs.
- Boston Scientific: Boston Scientific markets the Promus/Promus Element and SYNERGY drug-eluting stents. Like Abbott and Medtronic, it represents a top-three incumbent competitor and potential acquirer of differentiated stent technology.
- Terumo: Terumo distributes the Ultimaster and previously MiStent coronary stents globally with deep cath-lab relationships. Comparable as a broad incumbent with overlapping interventional cardiology products that could partner with or absorb Svelte.
- Cordis (Cardinal Health): Cordis, now part of Cardinal Health, historically created the CYPHER sirolimus-eluting stent and re-entered the coronary stent market. Comparable as a legacy incumbent with renewed interest in differentiated stent IP.
Direct peers
- Biotronik: Biotronik markets the Orsiro and PRO-Kinetic stent families, with a strong presence in Europe and a comparable mid-sized challenger profile to Svelte in the coronary and peripheral stent space.
- B. Braun: B. Braun's interventional cardiology unit sells the Coroflex and SeQuent Please drug-eluting stent and balloon-deliverable platforms. Comparable as a privately oriented, non-top-three competitor with overlapping deliverability-focused designs.
- Biosensors International: Biosensors developed the BioMatrix and Axxion stent platforms before strategic restructuring. Comparable as a mid-sized coronary stent specialist whose trajectory illustrates both the upside and exit paths available to Svelte.
- Elixir Medical: Elixir Medical develops the DESyne and DynamX bioadaptive coronary stent systems. Closely comparable as a similarly sized, venture-backed challenger focused on next-generation deliverable and adaptive stent designs.
Emerging players
- Lepu Medical: Lepu Medical markets the Partner and Nano drug-eluting stent lines, primarily in Asia and emerging markets. Comparable as an emerging challenger in coronary stents with comparable deliverability-focused product positioning outside the top three.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Svelte Medical Systems social profiles
Digital presenceSvelte Medical Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Svelte Medical Systems leadership team
Management profileNumber of profiles
Profiles7 records
Svelte Medical Systems funding detail
Funding detailFunding overview
Funding rounds11 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Svelte Medical Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Svelte Medical Systems
What does Svelte Medical Systems do?
Svelte Medical Systems designs and develops highly deliverable balloon-expandable stents for use in interventional cardiology procedures. The company focuses on stent and delivery system engineering intended to enable treatment of complex coronary lesions. Its offerings target hospitals and cardiology practices performing percutaneous coronary intervention.
Is Svelte Medical Systems a public or private company?
Svelte Medical Systems is a private company. It is classified as venture growth investor backed and is currently operating.
When was Svelte Medical Systems founded?
Svelte Medical Systems was founded in 2007. It employs 11 to 50 people.
Where is Svelte Medical Systems based?
Svelte Medical Systems is headquartered in New Providence, United States, in the North America region.
Who are Svelte Medical Systems's main competitors?
Broad incumbents on record are Abbott Vascular, Medtronic, Boston Scientific, Terumo and Cordis (Cardinal Health). Direct peers are Biotronik, B. Braun, Biosensors International and Elixir Medical. Lepu Medical is listed as an emerging player.
Does Svelte Medical Systems have an API?
No public API is recorded for Svelte Medical Systems.
What industry is Svelte Medical Systems in?
Svelte Medical Systems's product category is Interventional Cardiology Medical Devices. Its primary akta.pro industry code is HLAHAFAA, Coronary Stents & Drug-Eluting Technologies, with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its NAICS code is 339113 and its SIC code is 3841.